Important Innovations Collection

  D AILY INNOVATION BRIEF                                                                                                          By Journalists Edward Kane & Maryanne Kane  CLIMATE CHANGE & YOUR 9 TO 5 LIFE                                             Source: Stock Summer 2023 In the US and Europe this summer, sweltering heatwaves with temperatures and humidity pushing historic records are making work life unbearable for millions Experts are saying  conditions are so uncomfortable that working hours may have to be adjusted to help peopl...

Oxford University Global Study Says Majority Are Not Source:  NASA  Power Companies and the Fight Against Climate Change A new study by scientists at Oxford University in the UK suggests that power companies are very slow to support and utilize green, renewable energy sources like wind and solar power.  In fact, of the 3,000 power utility companies around the world that the Oxford researchers studied, only 10% of the energy suppliers have prioritized renewables over fossil fuels.  Many continue to invest in fossil fuels. The study concludes that utilities' slowness to embrace renewable energy sources is undermining the fight against Climate Change. Europe Coming on Green Europe is ahead of the curve in using renewables.  For instance, 40% of the United Kingdom's electricity is coming from wind and solar.  But globally, many of the new wind and solar instillations are being built by independent producers not by utilities. Comprehensive 20 Year Study and Ana...

Closing in on COVID Vaccines Source:  European Commission President Ursula Von Der Leyen & Council President Charles Michel EU Historic Stimulus Package Researchers at Oxford University in the UK, along with AstraZeneca, have developed a COVID vaccine that is proving to be successful at building immunity against COVID.  Human trials on more than 1000 patients have proven the vaccine effective.  The vaccine has moved into combined Phase 2 and Phase 3 trials - the last stop to prove it works.  AstraZeneca has a $1.2 billion deal with the US to deliver 300 million doses this fall, if the vaccine is approved. Two More Vaccines Meanwhile, at Moderna Pharma in Cambridge, MA, an experimental mRNA vaccine is in human trials and it is proving to be effective. It has produced antibodies in all the patients involved in the trials And, in China biotech Cansino's vaccine is showing positive antibody responses in a Phase 2 trial.  It is entering Phase 3 ...

Promising Oxford University Vaccine Source:  Gilead Sciences Successful Gilead Sciences Treatment In the war against COVID-19, some good news.  Gilead Sciences' remdesivir has shown improvement in patients taking it to treat the virus. That, according to Gilead's own study.  On top of that, testing by the National Institution of Allergy and Infectious Disease also gave the drug "positive data" results in their own testing.  This news raised hopes on Wall Street that a treatment/cure is near and that the economy may be able to open safely again.  At the start of trading, the DJIA shot up 400 points and Gilead shares were up 9.3%. Promising Vaccine Meanwhile, researchers at Oxford University in the UK say they could  have a COVID-19 vaccine ready for humans by the 4th quarter of this year. Their experimental vaccine has proven effective in protecting monkeys from the virus.  Monkeys given the vaccine did not catc...